- Perrigo Company plc recently took part in the UBS Global Consumer and Retail Conference in New York, where President and CEO Patrick Lockwood-Taylor presented the company’s outlook and priorities to investors and industry participants.
- This conference appearance gave investors a direct window into management’s latest thinking on business focus, operational initiatives, and potential portfolio evolution, which can influence how the company’s longer-term position is understood.
- Next, we’ll consider how CEO Patrick Lockwood-Taylor’s conference remarks might shape Perrigo’s investment narrative and key business assumptions.
AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Perrigo Investment Narrative Recap
To own Perrigo, you generally need to believe that consumer cost-consciousness and self-care habits will support its store-brand OTC and nutrition portfolio despite recent losses and slow revenue trends. The UBS Global Consumer and Retail Conference appearance itself does not materially change the near term picture: the key catalyst remains execution on cost savings and portfolio focus, while the biggest risk is continued weak category consumption and competitive pressure that could weigh further on margins.
Among recent announcements, the fresh 2026 guidance for net sales of negative to modest decline (between -5.5% and -1.5% versus 2025) is most relevant here. It frames the context for what investors may listen for at the UBS conference: how management plans to offset category softness, operational issues such as infant formula variability, and margin pressure while still funding innovation and private label growth initiatives.
Yet against this backdrop, investors should also be aware that...
Read the full narrative on Perrigo (it's free!)
Perrigo's narrative projects $4.6 billion revenue and $183.6 million earnings by 2028. This requires 1.7% yearly revenue growth and a $243.1 million earnings increase from -$59.5 million today.
Uncover how Perrigo's forecasts yield a $17.00 fair value, a 80% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts, who once modeled Perrigo reaching about US$4.7 billion in revenue and roughly US$200 million in earnings by 2028, see deepening retail partnerships as a powerful offset to risks like retailer dependence. Their view is far more upbeat than consensus, and the latest UBS appearance could reinforce or challenge that, so it is worth comparing how your own expectations line up with these very different scenarios.
Explore 4 other fair value estimates on Perrigo - why the stock might be worth over 5x more than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Perrigo research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Perrigo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Perrigo's overall financial health at a glance.
Contemplating Other Strategies?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com